Acrivon Therapeutics, Common Stock In The News

ACRV Stock   5.44  0.37  7.30%   
Our overall analysis of Acrivon Therapeutics,'s news coverage and content from conventional and social sources shows investors' bearish mood towards Acrivon Therapeutics, Common. The specific impact of Acrivon Therapeutics, news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Acrivon Therapeutics,'s overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Acrivon Therapeutics, headlines in addition to utilizing other, more conventional financial analysis modules. Check out Acrivon Therapeutics, Backtesting and Acrivon Therapeutics, Hype Analysis.

Acrivon Therapeutics, Today Top News and Investor Outlook

Macroaxis News: globenewswire.com
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Ovarian Cancer
https://www.globenewswire.com/news-release/2023/11/28/2786894/0/en/Acrivon-Therapeutics-Announces-FDA-has-Granted-Breakthrough-Device-Designation-for-ACR-368-OncoSignature-Assay-for-Ovarian-Cancer.html
 Neutral
Macroaxis News: globenewswire.com
Acrivon Therapeutics to Present at the Piper Sandler Annual Healthcare Conference
https://www.globenewswire.com/news-release/2023/11/21/2783995/0/en/Acrivon-Therapeutics-to-Present-at-the-Piper-Sandler-Annual-Healthcare-Conference.html
 Neutral
Macroaxis News: globenewswire.com
Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2023/11/21/2783998/0/en/Acrivon-Therapeutics-Announces-Inducement-Grant-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Neutral
Macroaxis News: globenewswire.com
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
https://www.globenewswire.com/news-release/2023/11/09/2777325/0/en/Acrivon-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Business-Highlights.html
 Neutral
Macroaxis News: globenewswire.com
Acrivon Therapeutics Presents Data Demon...
https://www.globenewswire.com/news-release/2023/10/16/2760588/0/en/Acrivon-Therapeutics-Presents-Data-Demonstrating-Capabilities-of-its-AP3-Platform-and-ACR-368-OncoSignature-Assay-for-Patient-Responder-Identification-at-the-AACR-NCI-EORTC-Interna.html
 Neutral
Macroaxis News: globenewswire.com
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2023/09/28/2751631/0/en/Acrivon-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Neutral
Macroaxis News: globenewswire.com
Acrivon Therapeutics to Highlight its AC...
https://www.globenewswire.com/news-release/2023/09/19/2746037/0/en/Acrivon-Therapeutics-to-Highlight-its-ACR-368-OncoSignature-Test-Used-in-Ongoing-Phase-2-Study-to-Treat-Patients-Based-on-Predicted-Sensitivity-to-Monotherapy-with-its-CHK1-2-Inhib.html
 Neutral
Macroaxis News: globenewswire.com
Acrivon Therapeutics Announces ACR-2316,...
https://www.globenewswire.com/news-release/2023/09/05/2737869/0/en/Acrivon-Therapeutics-Announces-ACR-2316-a-Novel-Dual-WEE1-and-PKMYT1-Inhibitor-Development-Candidate-Designed-Using-Acrivon-s-AP3-Platform-to-Achieve-Potent-Single-Agent-Activity-a.html
 Neutral
Macroaxis News: globenewswire.com
Acrivon Therapeutics to Participate in Two Investor Conferences in September
https://www.globenewswire.com/news-release/2023/08/30/2734273/0/en/Acrivon-Therapeutics-to-Participate-in-Two-Investor-Conferences-in-September.html
 Neutral
Macroaxis News: globenewswire.com
Acrivon Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
https://www.globenewswire.com/news-release/2023/08/17/2727640/0/en/Acrivon-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html
 Neutral

Acrivon Therapeutics, Common Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Acrivon and other traded companies coverage with news coverage. We help investors stay connected with Acrivon headlines for the 15th of March 2025 to make an informed investment decision based on correlating the impacts of news items on Acrivon Stock performance. Please note that trading solely based on the Acrivon Therapeutics, Common hype is not for everyone as timely availability and quick action are needed to avoid losses.
Acrivon Therapeutics,'s linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Acrivon Therapeutics, Common investors visualize upcoming and past events in order to time the market based on Acrivon Therapeutics, Common noise-free hype analysis.
Acrivon Therapeutics, stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Acrivon earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Acrivon Therapeutics, that are available to investors today. That information is available publicly through Acrivon media outlets and privately through word of mouth or via Acrivon internal channels. However, regardless of the origin, that massive amount of Acrivon data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Acrivon Therapeutics, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Acrivon Therapeutics, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Acrivon Therapeutics,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Acrivon Therapeutics, alpha.

Acrivon Largest EPS Surprises

Earnings surprises can significantly impact Acrivon Therapeutics,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2024-05-14
2024-03-31-0.84-0.730.1113 
2024-03-28
2023-12-31-0.73-0.86-0.1317 
2023-03-28
2022-12-31-1.09-0.80.2926 
View All Earnings Estimates

Acrivon Therapeutics, Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Acrivon Therapeutics, Stock. Current markets are strongly bullish. About 93% of major world exchanges and indexes are currently up. See today's market update for more information.
Google News at Macroaxis
11th of March 2025
Acrivon Therapeutics Stock Is Soaring Tuesday Whats Going On - MSN
at news.google.com 
Macroaxis News
21st of February 2025
Disposition of 19904 shares by Blume-jensen Peter of Acrivon Therapeutics, at 5.54 subject...
at MacroaxisInsider 
Macroaxis News
14th of February 2025
Disposition of 579 shares by Blume-jensen Peter of Acrivon Therapeutics, at 5.42 subject t...
at MacroaxisInsider 
Yahoo News
5th of February 2025
Acrivon Therapeutics AI-Powered Precision Oncology Gets FDA Breakthrough Status
at finance.yahoo.com 
news
31st of January 2025
Cantor Fitzgerald Initiates Coverage on Acrivon Therapeutics
at thelincolnianonline.com 
Google News at Macroaxis
17th of December 2024
Acrivon Therapeutics SWOT analysis oncology innovators stock faces pivotal phase - Investi...
at news.google.com 

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Acrivon Therapeutics, in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Acrivon Therapeutics,'s short interest history, or implied volatility extrapolated from Acrivon Therapeutics, options trading.

Additional Tools for Acrivon Stock Analysis

When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.